MA27699A1 - Vaccin contre vhc - Google Patents

Vaccin contre vhc

Info

Publication number
MA27699A1
MA27699A1 MA28284A MA28284A MA27699A1 MA 27699 A1 MA27699 A1 MA 27699A1 MA 28284 A MA28284 A MA 28284A MA 28284 A MA28284 A MA 28284A MA 27699 A1 MA27699 A1 MA 27699A1
Authority
MA
Morocco
Prior art keywords
methods
hcv
vaccine against
against hcv
vaccines
Prior art date
Application number
MA28284A
Other languages
English (en)
French (fr)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27699A1 publication Critical patent/MA27699A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA28284A 2002-11-15 2005-05-16 Vaccin contre vhc MA27699A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
MA27699A1 true MA27699A1 (fr) 2006-01-02

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc
MA28285A MA27700A1 (fr) 2002-11-15 2005-05-16 Vaccin contre l'hepatite c

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA28285A MA27700A1 (fr) 2002-11-15 2005-05-16 Vaccin contre l'hepatite c

Country Status (21)

Country Link
US (4) US20060246090A1 (enExample)
EP (2) EP1560845A1 (enExample)
JP (2) JP2006518331A (enExample)
KR (2) KR20050085010A (enExample)
CN (2) CN1738834A (enExample)
AR (1) AR041964A1 (enExample)
AU (2) AU2003288084A1 (enExample)
BR (2) BR0316244A (enExample)
CA (2) CA2504654A1 (enExample)
CO (1) CO5700833A2 (enExample)
GB (1) GB0226722D0 (enExample)
IS (2) IS7830A (enExample)
MA (2) MA27699A1 (enExample)
MX (2) MXPA05005203A (enExample)
NO (2) NO20052136L (enExample)
NZ (2) NZ539999A (enExample)
PL (2) PL376967A1 (enExample)
RU (2) RU2363492C2 (enExample)
TW (1) TW200502246A (enExample)
WO (2) WO2004046175A1 (enExample)
ZA (2) ZA200503803B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
EP1993603B1 (en) * 2006-03-09 2012-05-02 Transgene SA Hepatitis c virus non structural fusion protein
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
KR20110045010A (ko) * 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
NZ296304A (en) * 1994-10-05 1999-06-29 Apollon Hepatitis c vaccine components
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
AU774887B2 (en) * 1999-07-09 2004-07-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
DE60036881T2 (de) * 1999-11-24 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Neues nichtstrukturelles hcv-polypeptid
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
US20090104231A1 (en) 2009-04-23
WO2004046175A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
RU2005113691A (ru) 2006-01-27
PL376882A1 (pl) 2006-01-09
TW200502246A (en) 2005-01-16
MXPA05005202A (es) 2006-01-27
NZ539998A (en) 2008-04-30
JP2006518331A (ja) 2006-08-10
CN1738833A (zh) 2006-02-22
ZA200503802B (en) 2006-08-30
NO20052136D0 (no) 2005-05-02
US20060246090A1 (en) 2006-11-02
NO20052149D0 (no) 2005-05-02
NO20052136L (no) 2005-07-11
WO2004046176A1 (en) 2004-06-03
BR0316291A (pt) 2005-10-11
KR20050085010A (ko) 2005-08-29
IS7830A (is) 2005-04-28
MXPA05005203A (es) 2006-01-27
CA2504654A1 (en) 2004-06-03
EP1560844A1 (en) 2005-08-10
MA27700A1 (fr) 2006-01-02
KR20050085009A (ko) 2005-08-29
NO20052149L (no) 2005-07-11
PL376967A1 (pl) 2006-01-23
CO5700833A2 (es) 2006-11-30
NZ539999A (en) 2008-03-28
US20090232847A1 (en) 2009-09-17
GB0226722D0 (en) 2002-12-24
AR041964A1 (es) 2005-06-01
AU2003288084A1 (en) 2004-06-15
IS7831A (is) 2005-04-28
ZA200503803B (en) 2006-08-30
BR0316244A (pt) 2005-10-04
AU2003288072A1 (en) 2004-06-15
RU2323744C2 (ru) 2008-05-10
US20060135451A1 (en) 2006-06-22
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
RU2363492C2 (ru) 2009-08-10
JP2006524181A (ja) 2006-10-26
EP1560845A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EP1322338A4 (en) COMPOSITIONS AND METHODS FOR USE OF THE CAPSID PROTEIN FROM FLAVIVIRES OR PESTVIRUSES
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ATE512976T1 (de) Hemmer des hepatitis-c-virus
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
WO2005002526A3 (en) Method and compositions for treatment of viral infections
MA30670B1 (fr) Vaccins contre le paludisme
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
MA27474A1 (fr) Vaccin
TW200509964A (en) VP1 of foot-and-mouth disease virus